Premium
Insulin‐like growth factor‐1 receptor inhibition overcomes gefitinib resistance in mucinous lung adenocarcinoma
Author(s) -
Hurbin Amandine,
Wislez Marie,
Busser Benoît,
Antoine Martine,
Tenaud Corine,
Rabbe Nathalie,
Dufort Sandrine,
de Fraipont Florence,
MoroSibilot Denis,
Cadranel Jacques,
Coll JeanLuc,
Brambilla Elisabeth
Publication year - 2011
Publication title -
the journal of pathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.964
H-Index - 184
eISSN - 1096-9896
pISSN - 0022-3417
DOI - 10.1002/path.2897
Subject(s) - gefitinib , amphiregulin , epidermal growth factor receptor , adenocarcinoma , kras , cancer research , medicine , erlotinib , lung cancer , mucinous carcinoma , oncology , cancer , colorectal cancer
The appropriate selection of patients is a major challenge in the treatment of non‐small cell lung cancer (NSCLC) with epidermal growth factor receptor‐tyrosine kinase inhibitors (EGFR‐TKIs). Prospective trials in adenocarcinoma demonstrated that the mucinous subtype presents a poorer outcome under EGFR‐TKI treatment than the non‐mucinous subtype. Our aim was to determine the molecular characteristics associated with resistance to EGFR‐TKIs in mucinous and non‐mucinous adenocarcinoma. Eighty adenocarcinoma samples, including 34 tumours from patients treated with gefitinib in a phase II clinical trial (IFCT0401), were classified as mucinous ( n = 32) or non‐mucinous ( n = 48) adenocarcinoma. We demonstrated that four biological markers were differentially expressed between the two subtypes: mucinous tumours that overexpressed IGF1R ( p < 0.0001) and amphiregulin ( p = 0.004) with a tendency for more frequent KRAS mutations, in contrast to non‐mucinous tumours that overexpressed EGFR ( p < 0.0001) and TTF‐1 ( p < 0.0001) with more frequent EGFR mutations ( p = 0.037). Higher IGF1R ( p = 0.02) and lower TTF‐1 ( p = 0.02) expression was associated with disease progression under gefitinib treatment. We observed in vitro cross‐talk between EGFR and IGF1R signalling pathways in gefitinib‐resistant H358 mucinous cells. Anti‐amphiregulin siRNAs and anti‐IGF1R treatments sensitized the H358 cells to gefitinib‐induced apoptosis with additive effects, suggesting that these treatments could overcome the resistance of mucinous tumours to EGFR‐TKIs, including those with KRAS mutation. Our results highlighted that mucinous and non‐mucinous adenocarcinoma subtypes are different entities with different therapeutic responses to EGFR‐TKIs. These data will foster the development of therapeutic strategies for treating adenocarcinoma with mucinous component. Copyright © 2011 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.